Evidence map›Paper›PMID 35439678›Full record

ReviewEBioMedicine2022

Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.

Honggang Ying, Jian Xu, Xiaozhen Zhang, Tingbo Liang, Xueli Bai

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Memory-promoting function of miR-379-5p attenuates CD8Journal for immunotherapy of cancer · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. COPD and Immune Checkpoint Inhibitors for Cancer: A Literature Review.International journal of chronic obstructive pulmonary disease · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Honggang YingDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, , 79 Qingchun Road, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Innovation Centre for the Study of Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Clinical Research Centre for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Cancer Centre, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Jian XuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, , 79 Qingchun Road, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Innovation Centre for the Study of Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Clinical Research Centre for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Cancer Centre, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Xiaozhen ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, , 79 Qingchun Road, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Innovation Centre for the Study of Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Clinical Research Centre for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Cancer Centre, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, , 79 Qingchun Road, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Innovation Centre for the Study of Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Clinical Research Centre for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Cancer Centre, Zhejiang University, Hangzhou, Zhejiang 310058, China. Electronic address: liangtingbo@zju.edu.cn.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, , 79 Qingchun Road, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Innovation Centre for the Study of Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Zhejiang Provincial Clinical Research Centre for the Study of Hepatobiliary & Pancreatic Diseases, Hangzhou, Zhejiang 310003, China; Cancer Centre, Zhejiang University, Hangzhou, Zhejiang 310058, China. Electronic address: shirleybai@zju.edu.cn.
Zhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) is a newly emerging immune checkpoint that belongs to B7 family. HHLA2 has a co-stimulatory receptor transmembrane and immunoglobulin domain containing 2 (TMIGD2) and a newly discovered co-inhibitory receptor killer cell Ig-like receptor, three Ig domains, and long cytoplasmic tail (KIR3DL3), which endows it with both immunostimulant and immunosuppression functions in cancer development. In this review, we summarize the HHLA2 expression profile in human cancers, its association with cancer prognosis and clinical features, and its dual roles in regulating cancer immune response through up-to-date literatures. Furthermore, we highlight that precision cancer immunotherapy through manipulating HHLA2-KIR3DL3/TMIGD2 interaction is a promising antitumour strategy.

Indexed as

Endogenous RetrovirusesImmune Checkpoint ProteinsImmunoglobulinsNeoplasmsHumansImmunotherapyTerminal Repeat SequencesHHLA2 protein, humanImmune Checkpoint ProteinsImmunoglobulinsCancer immunotherapyHHLA2Immune checkpointKIR3DL3TMIGD2

Identifiers

PMID35439678
PMCPMC9035628
OpenAlexW4224140575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.